WEIGHT-LOSS jabs are the most talked about drugs of the moment. And with new studies popping up almost every week revealing more benefits of these powerful medicines, it’s no wonder appetite ...
The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with T2D.
WEIGHT-LOSS jabs are the most talked about drugs of the moment. And with new studies popping up almost every week revealing ...
President Biden and Sen. Bernie Sanders (I-Vt.) will travel to New Hampshire on Tuesday to speak on health care savings ...
Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings ...
When the Danish government in January presented the first of its schemes to make it easier to recruit foreign labour from ...
The Wegovy makers’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in ...
For the first time in a decade, the American Heart Association and American Stroke Association issued new recommendations for ...
Novo Nordisk said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular ...
Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the ...
Morgan Stanley and Goldman Sachs issued bullish notes on BioAge (BIOA) based on its obesity drug candidate azelaprag and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback